Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis $122.35 -4.42 (-3.49%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Natera Stock (NASDAQ:NTRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Natera alerts:Sign Up Key Stats Today's Range$122.32▼$127.7950-Day Range$107.70▼$131.9352-Week Range$36.90▼$133.54Volume734,835 shsAverage Volume1.34 million shsMarket Capitalization$15.02 billionP/E RatioN/ADividend YieldN/APrice Target$122.73Consensus RatingBuy Company OverviewNatera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More… Here’s how to start a “Weekend Side Hustle” from your sofa (Ad)Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand. And that’s how you can kickstart your very own “Weekend Side Hustle!” Now that you know that…Let me show you how I target extra income as early as THIS weekend! Natera Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks42nd Percentile Overall ScoreNTRA MarketRank™: Natera scored higher than 42% of companies evaluated by MarketBeat, and ranked 738th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNatera has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Natera's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($1.96) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -49.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -49.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 19.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Natera's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.99% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Natera has recently decreased by 2.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.99% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Natera has recently decreased by 2.90%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment0.85 News SentimentNatera has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Natera this week, compared to 8 articles on an average week.Search InterestOnly 1 people have searched for NTRA on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat Follows7 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,426,901.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Natera's insider trading history. Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRA Stock News HeadlinesJonathan Sheena Sells 3,000 Shares of Natera, Inc. (NASDAQ:NTRA) StockOctober 4, 2024 | insidertrades.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 2,700 Shares of StockSeptember 21, 2024 | insidertrades.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 17, 2024 | Timothy Sykes (Ad)Natera, Inc. (NASDAQ:NTRA) CEO Sells $645,483.52 in StockSeptember 20, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Director Rowan E. Chapman Sells 2,614 SharesSeptember 17, 2024 | insidertrades.comNatera (NASDAQ:NTRA) Stock Quotes, Forecast and News SummaryOctober 13, 2024 | benzinga.comNatera (NTRA) Soared After a 43% Increase In RevenueOctober 10, 2024 | msn.comCareDx stock climbs 7% amid reports Natera not pursuing litigationOctober 10, 2024 | msn.comSee More Headlines NTRA Stock Analysis - Frequently Asked Questions How have NTRA shares performed this year? Natera's stock was trading at $62.64 at the beginning of the year. Since then, NTRA stock has increased by 95.3% and is now trading at $122.35. View the best growth stocks for 2024 here. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) announced its earnings results on Thursday, August, 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. The company's quarterly revenue was up 58.1% on a year-over-year basis. When did Natera IPO? Natera (NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Natera's top institutional shareholders include Artemis Investment Management LLP (0.22%), Handelsbanken Fonder AB (0.08%), SWS Partners (0.05%) and Royal Fund Management LLC (0.01%). Insiders that own company stock include Matthew Rabinowitz, Daniel Rabinowitz, Steven Leonard Chapman, Solomon Moshkevich, John Fesko, Michael Burkes Brophy, Herm Rosenman, Jonathan Sheena, James Healy, Gail Boxer Marcus, Rowan E Chapman, Robert Alan Schueren and Roelof Botha. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,293Year FoundedN/APrice Target and Rating Average Stock Price Target$124.44 High Stock Price Target$150.00 Low Stock Price Target$70.00 Potential Upside/Downside+0.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,800,000.00 Net Margins-21.47% Pretax Margin-21.35% Return on Equity-36.74% Return on Assets-19.90% Debt Debt-to-Equity Ratio0.34 Current Ratio4.14 Quick Ratio4.01 Sales & Book Value Annual Sales$1.36 billion Price / Sales11.04 Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book19.21Miscellaneous Outstanding Shares122,803,000Free Float114,281,000Market Cap$15.02 billion OptionableOptionable Beta1.53 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:NTRA) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.